Mutant p53 rescue and modulation of p53 redox state

被引:39
作者
Bykov, Vladimir J. N. [1 ]
Lambert, Jeremy M. R. [1 ]
Hainaut, Pierre [2 ]
Wiman, Klas G. [1 ]
机构
[1] Karolinska Inst, CCK, Dept Oncol Pathol, S-17176 Stockholm, Sweden
[2] IARC, Lyon, France
关键词
p53; redox regulation; mutant p53 rescue; PRIMA-1; apoptosis; cancer therapy; ANTICANCER DRUG ELLIPTICINE; TUMOR-SUPPRESSOR; DNA-BINDING; WILD-TYPE; CYTOCHROMES P450; ZINC-BINDING; RESTORATION; MUTATIONS; CANCER; CELLS;
D O I
10.4161/cc.8.16.9382
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The p53 tumor suppressor is a key regulator of cell growth and survival upon various forms of cellular stress. p53 is a redox-regulated transcription factor that binds specifically to DNA and activates transcription of target genes. The core domain of p53 holds a zinc atom that protects p53 from oxidation and is critical for DNA binding. A large fraction of human tumors carry p53 mutation, allowing evasion of apoptosis and tumor progression. Restoration of wild type p53 expression triggers rapid elimination of tumors in vivo. This makes mutant p53 an attractive target for novel cancer therapy. Small molecules have been identified that reactivate mutant p53 and induce apoptosis in tumor cells. Interestingly, several of these compounds share the ability to target thiols and affect the redox state of p53, indicating that this is critical for mutant p53 rescue. The identification of a common chemical activity among mutant p53-targeting compounds will facilitate the design of even more potent and selective mutant p53-targeting drugs for improved cancer therapy in the future.
引用
收藏
页码:2509 / 2517
页数:9
相关论文
共 64 条
[1]   TIGAR, a p53-inducible regulator of glycolysis and apoptosis [J].
Bensaad, Karim ;
Tsuruta, Atsushi ;
Selak, Mary A. ;
Calvo Vidal, M. Nieves ;
Nakano, Katsunori ;
Bartrons, Ramon ;
Gottlieb, Eyal ;
Vousden, Karen H. .
CELL, 2006, 126 (01) :107-120
[2]   Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer [J].
Berns, EMJJ ;
van Staveren, IL ;
Look, MP ;
Smid, M ;
Klijn, JGM ;
Foekens, JA .
BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1130-1136
[3]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[4]  
Borresen-Dale AL, 1998, CLIN CANCER RES, V4, P203
[5]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[6]   Thermodynamic stability of wild-type and mutant p53 core domain [J].
Bullock, AN ;
Henckel, J ;
DeDecker, BS ;
Johnson, CM ;
Nikolova, PV ;
Proctor, MR ;
Lane, DP ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14338-14342
[7]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[8]   Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs [J].
Bykov, VJN ;
Issaeva, N ;
Zache, N ;
Shilov, A ;
Hultcrantz, M ;
Bergman, J ;
Selivanova, G ;
Wiman, KG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (34) :30384-30391
[9]   PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis [J].
Bykov, VJN ;
Zache, N ;
Stridh, H ;
Westman, J ;
Bergman, J ;
Selivanova, G ;
Wiman, KG .
ONCOGENE, 2005, 24 (21) :3484-3491
[10]   Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database [J].
Bykov, VJN ;
Issaeva, N ;
Selivanova, G ;
Wiman, KG .
CARCINOGENESIS, 2002, 23 (12) :2011-2018